This product is a part of intravenous nutrition, used to supplement the daily physiological needs of various water-soluble vitamins so that the body's relevant biochemical reactions can proceed normally.

This product is an anti-deoxyribonucleic acid (DNA) virus drug. Its pharmacological action is to bind to the viral deoxyribonucleic acid polymerase, reduce its activity and inhibit DNA synthesis. After entering the cell, adenosine monophosphate is phosphorylated to generate adenosine diphosphate (Ara-ADP) and adenosine triphosphate (Ara-ATP). The antiviral activity is mainly caused by adenosine triphosphate (Ara-ATP). Ara-ATP and deoxyadenosine triphosphate (dATP) compete to bind to viral DNAP, thereby inhibiting the activity of the enzyme and the synthesis of viral DNA. At the same time, it inhibits the activity of viral nucleotide reductase and inhibits the synthesis of viral DNA. It can also inhibit the activity of viral DNA terminal deoxynucleotidyl transferase, so that Ara-A penetrates into the viral DNA and connects to the end of the DNA chain 3prime;-OH position, inhibiting the continued synthesis of viral DNA.

This product is an anti-deoxyribonucleic acid (DNA) virus drug. Its pharmacological action is to bind to the viral deoxyribonucleic acid polymerase, reduce its activity and inhibit DNA synthesis. After entering the cell, adenosine monophosphate is phosphorylated to generate adenosine diphosphate (Ara-ADP) and adenosine triphosphate (Ara-ATP). The antiviral activity is mainly caused by adenosine triphosphate (Ara-ATP). Ara-ATP and deoxyadenosine triphosphate (dATP) compete to bind to viral DNAP, thereby inhibiting the activity of the enzyme and the synthesis of viral DNA. At the same time, it inhibits the activity of viral nucleotide reductase and inhibits the synthesis of viral DNA. It can also inhibit the activity of viral DNA terminal deoxynucleotidyl transferase, so that Ara-A penetrates into the viral DNA and connects to the end of the DNA chain 3prime;-OH position, inhibiting the continued synthesis of viral DNA.

Pharmacological effects extracted from the above information

It has high antibacterial activity against most aerobic Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae and Oxytobacter, aerogenes, Cloacae, Proteus, Serratia, Citrobacter, Shigella and other Enterobacteriaceae, as well as influenza bacilli, gonococci, meningococci, etc. It also has good antibacterial effect against Pseudomonas aeruginosa, but has poor antibacterial effect against some Pseudomonas and Acinetobacter species other than Pseudomonas aeruginosa, and has no antibacterial activity against aerobic Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as anaerobic bacteria. Aztreonam exerts its antibacterial effect by binding to penicillin-binding protein 3 (PBP3) on the cell membrane of sensitive aerobic Gram-negative bacteria and interfering with the synthesis of bacterial cell walls.